The global Europe Circulating Tumor Cells (CTC) Liquid Biopsy market report deals with a number of industry and market parameters including latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights and innovation. This market report estimates compound annual growth rate (CAGR) value fluctuation for the forecast period of 2018-2025 that helps businesses make out the investment value. This market analysis offers an examination of various segments that are supposed to witness the quickest development amid the estimated forecast frame. Market research analysis performed in this report optimistically lends a hand to businesses for the strategy planning related to production, costing, inventory, purchasing and marketing.
86b46a58-12f0-2841-7e83-ffae3b4901f4
Europe circulating tumor cells (CTC) liquid biopsy market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 24.3% in the forecast period of 2022 to 2029 and is expected to reach USD 1,891.60 million by 2029 from USD 351.05 million in 2021. The high prevalence of chronic diseases and increasing R&D activities for its effective application is likely to be the major drivers which propel the demand of the market in the forecast period.
 
 
The liquid biopsy is a non-invasive blood test which detects circulating tumor cells and tumor DNA fragments which are released into the blood from primary tumors and metastatic sites. It is a simple and precise alternative to surgical biopsy procedure, which allows surgeon to detect cancer at a very early stage.
 
The major companies which are dealing in the circulating tumor cells (CTC) liquid biopsy market are Eurofins Genomics ( a subsidiary of Eurofins Scientific), MDx Health, Guardant Health, IMMUCOR, Thermo Fisher Scientific, Inc., Menarini Silicon Biosystems, QIAGEN, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc. , Natera Inc.,  ExoDx ( a subsidiary of Bio-Techne Corporation), Biocept, Inc., F. Hoffman-La Roche Ltd. ,FOUNDATION MEDICINE, INC., Lucence Health, Inc., Inivata Ltd, Biolidics Limited, Vortex Biosciences among others.
 
For instance,
 
In November 2021, Myriad Genetics, Inc. announced that it had received accreditation from College of American Pathologists. This will increase the market position of the company.
 
Collaboration, joint ventures, and other strategies by the market player is enhancing the company market in the circulating tumor cells (CTC) liquid biopsy market, which also provides the benefit for the organization to improve their offering for circulating tumor cells (CTC) liquid biopsy market.
 
 
Browse Trending Reports:
 
 
 
 
 
 
About Data Bridge Market Research:
 
An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.
 
Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.
 
Contact Us: -
 
Data Bridge Market Research
 
US: +1 888 387 2818
 
United Kingdom: +44 208 089 1725
 
Hong Kong: +852 8192 7475